Scarica l'app Stockscreener
28.80
0.35%
-0.10
Dopo l'orario di chiusura:
29.19
0.39
+1.35%
Precedente Chiudi:
$28.90
Aprire:
$28.12
Volume 24 ore:
646.25K
Relative Volume:
0.56
Capitalizzazione di mercato:
$2.53B
Reddito:
$218.71M
Utile/perdita netta:
$-113.70M
Rapporto P/E:
-22.10
EPS:
-1.3034
Flusso di cassa netto:
$-73.47M
1 W Prestazione:
-0.83%
1M Prestazione:
-12.03%
6M Prestazione:
-2.90%
1 anno Prestazione:
+40.69%
Intervallo 1D:
$27.93
$29.18
Intervallo di 1 settimana:
$27.89
$29.39
Portata 52W:
$16.82
$39.28
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Nome
Ideaya Biosciences Inc
Settore
Industria
Telefono
650-443-6209
Indirizzo
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
28.80 | 2.54B | 218.71M | -113.70M | -73.47M | -1.3034 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-09-18 | Iniziato | Guggenheim | Buy |
| 2025-09-04 | Iniziato | Barclays | Overweight |
| 2025-09-04 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-07-22 | Iniziato | TD Cowen | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-06-26 | Iniziato | Wells Fargo | Overweight |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-11-05 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2024-03-08 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Outperform |
| 2023-05-24 | Iniziato | Goldman | Buy |
| 2023-04-24 | Aggiornamento | Stifel | Hold → Buy |
| 2023-03-23 | Iniziato | Berenberg | Buy |
| 2023-02-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-12-28 | Iniziato | CapitalOne | Overweight |
| 2022-10-27 | Iniziato | Citigroup | Buy |
| 2022-08-15 | Downgrade | Stifel | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-10 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-11 | Iniziato | Guggenheim | Buy |
| 2020-10-07 | Iniziato | Wedbush | Outperform |
| 2020-09-01 | Iniziato | Northland Capital | Outperform |
| 2020-07-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-06 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-13 | Iniziato | ROTH Capital | Buy |
| 2019-10-17 | Iniziato | Oppenheimer | Outperform |
| 2019-09-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-17 | Iniziato | Citigroup | Buy |
| 2019-06-17 | Iniziato | JP Morgan | Neutral |
| 2019-06-17 | Iniziato | Jefferies | Buy |
Mostra tutto
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
IDEAYA Biosciences Files New Shelf Registration Statement - TipRanks
IDEAYA Biosciences, Inc. Files Form 8-K SEC Report for May 5, 2026 – Company Information and Common Stock Details - Minichart
IDEAYA (NASDAQ: IDYA) renews shelf, keeps $156.6M ATM capacity - Stock Titan
IDEAYA (NASDAQ: IDYA) has $156.55M ATM capacity remaining under Jefferies sales pact - Stock Titan
IDEAYA (NASDAQ: IDYA) files shelf to sell common stock, debt and warrants - Stock Titan
IDEAYA (NASDAQ: IDYA) reports Q1 loss but holds $972.9M cash - Stock Titan
IDEAYA Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
IDEAYA Biosciences 1Q Loss $98.5M >IDYA - Moomoo
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance Singapore
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update - BioSpace
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q1 Revenue $6.6M, vs. FactSet Est of $5.0M - marketscreener.com
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q1 Revenue $6.6M, Vs. FactSet Est of $5.0M - Moomoo
IDEAYA (IDYA) posts Q1 2026 loss, advances darovasertib NDA plan - Stock Titan
IDEAYA says eye cancer drug combo cut progression risk 58% - Stock Titan
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Quantisnow
Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now? - Insider Monkey
Technical Reactions to IDYA Trends in Macro Strategies - Stock Traders Daily
IDEAYA Biosciences, Inc. $IDYA Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Five new IDEAYA hires receive stock options at $29.10 a share - Stock Titan
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62 - Moomoo
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program - BioSpace
IDEAYA to file NDA for uveal melanoma drug under FDA fast review - Investing.com Canada
Executive pay and auditor vote headline IDEAYA (NASDAQ: IDYA) 2026 meeting - Stock Titan
Ideaya Biosciences gets coverage initiation at Barclays and Citizens - MSN
RBC Capital Maintains IDEAYA Biosciences (IDYA) Outperform Recommendation - MSN
IDEAYA Biosciences Advances Precision Oncology with AI Discovery - HarianBasis.co
IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush Highlights Positive OptimUM-02 Trial Readout - Insider Monkey
IDYA (IDEAYA Biosciences Inc.) posts narrower than expected Q4 2025 loss, shares rise 4.31 percent.Viral Momentum Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
IDYA (IDEAYA Biosciences Inc.) reports narrower Q4 2025 loss than projections, but stock dips slightly in today's trading.Pro Level Trade Signals - Xã Thanh Hà
IDEAYA and Servier's eye cancer drug meets trial goal, paving way for FDA application - MSN
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Mel - BioSpace
IDEAYA And AstraZeneca Collaboration Adds New Dimension To IDE849 And Valuation - simplywall.st
IDEAYA to present trial data at ASCO meeting in June By Investing.com - Investing.com Australia
IDEAYA to present trial data at ASCO meeting in June - Investing.com
Trading the Move, Not the Narrative: (IDYA) Edition - Stock Traders Daily
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 4.5%Here's Why - MarketBeat
Why IDEAYA Biosciences Stock Is Suddenly Sinking - TipRanks
IDEAYA gets late-breaking ASCO slot for full uveal melanoma data - Stock Titan
Is IDEAYA Biosciences (IDYA) stock risky for investors (Builds on Momentum) 2026-04-18AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
IDEAYA Biosciences (NASDAQ:IDYA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
IDEAYA Biosciences Inc : JP Morgan Raises Tar - Moomoo
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 3.5%Should You Sell? - MarketBeat
Ideaya Biosciences Stock Not Fully Reflecting Phase 2/3 Data From Metastatic Uveal Melanoma Study, RBC Says - marketscreener.com
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Trio of Bay Area cancer-fighting companies look to raise $1 billion on solid clinical trials - The Business Journals
IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars - Sahm
Guggenheim raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada
RBC Capital raises Ideaya Biosciences stock price target on trial data - Investing.com Canada
Tudor Investment Corp ET AL Purchases New Position in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Novo teams with OpenAI; Ideaya gets muted response to eye drug data - Yahoo Finance
Wedbush Forecasts Strong Price Appreciation for IDEAYA Biosciences (NASDAQ:IDYA) Stock - MarketBeat
Ideaya Biosciences Inc Azioni (IDYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):